Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low

MT Newswires Live

Jan 15, 2025

Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.

Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.

The application is expected to be approved in the first quarter of 2026, the filing said.

Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.

Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503679634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503679634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503679634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 08:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503679634","market":"sh","top_or_hot":-1,"title":"Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low","media":"MT Newswires Live","content":"<html><body><p> Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.</p><p>Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.</p><p>The application is expected to be approved in the first quarter of 2026, the filing said.</p><p>Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.</p><p>Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Says US Partner Filed Marketing Application for Rett Syndrome Drug Candidate; Shares Fall Near 1.5-Year Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-15 08:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.</p><p>Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.</p><p>The application is expected to be approved in the first quarter of 2026, the filing said.</p><p>Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.</p><p>Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503679634","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503679634","pubTimestamp":1736901677,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals'  partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The application is expected to be approved in the first quarter of 2026, the filing said.Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药","BK7508":"医药生物股"},"translate_title":"Neuren表示美国合作伙伴提交了雷特综合症候选药物的营销申请；股价跌至1.5年低点附近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The application is expected to be approved in the first quarter of 2026, the filing said.Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}